Status: Recruiting
LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.
A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis
Participants needed: 234
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Santen SASUpdated: May 4, 2026Locations: 36
Eligibility criteria
Able to understand and sign an informed consent form prior to participation in a... [+8]
Congenital ptosis. [+19]